Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis

Схожие документы

• Is T790M mutation the key in development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)?
  по: Takabe, Kazuaki
  Опубликовано: (2011)
• Efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports
  по: Liu, Yongmei, et al.
  Опубликовано: (2017)
• Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation
  по: Fang, Wenfeng, et al.
  Опубликовано: (2013)
• Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
  по: Gelatti, Ana, et al.
  Опубликовано: (2019)
• Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
  по: Russo, Alessandro, et al.
  Опубликовано: (2019)